Predicting response to PD-1 inhibitors in head and neck squamous cell carcinomas using peripheral blood inflammatory markers
Immune checkpoint inhibitor (ICI) treatment has the potential to induce durable disease remission. However, the current combined positive score (CPS) is insufficient accurate for predicting which patients will benefit from it. In the present study, a real-world retrospective study was conducted on 5...
Saved in:
| Main Authors: | Ruihua Fang, Yi Chen, Bixue Huang, Zhangfeng Wang, Xiaolin Zhu, Dawei Liu, Wei Sun, Lin Chen, Minjuan Zhang, Kexing Lyu, Wenbin Lei |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523324003486 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Natural killer cell in the development and treatment of head and neck squamous cell carcinoma
by: Lu-Ming WANG, et al.
Published: (2021-02-01) -
Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab
by: Xuefeng Wang, et al.
Published: (2025-03-01) -
Peripheral immune and inflammatory markers as predictors of neoadjuvant immunotherapy response in head and neck squamous cell carcinoma
by: Wendi Li, et al.
Published: (2025-12-01) -
Safety and efficacy of neoadjuvant therapy with tislelizumab plus chemotherapy for locally advanced head and neck squamous cell carcinoma: a single-arm, retrospective study
by: Haifeng Liang, et al.
Published: (2025-02-01) -
Successful treatment of recurrent unresectable squamous cell carcinoma of the head and neck using pembrolizumab
by: A. M. Mudunov, et al.
Published: (2019-04-01)